the Image

Clinical Trial Details

If you are a patient or a caregiver and would like to learn more our cancer clinical trials call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or email cancerclinicaltrials@bsd.uchicago.edu .

Share this:
Brief Title NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
Official Title A Phase II Open-Label Study of NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
Principal Investigator Moroney, John
Brief Summary This study will evaluate the effect of two dose levels of NUC-1031 (500 mg/m2 and 750mg/m2) in patients with ovarian cancer. The primary objective is to determine the anti-tumor activity of NUC-1031 at the selected dose level (500 mg/m2 or 750 mg/m2).
Gender Female
Ages 18 Years
Enrollment 64
Accepts Healthy Volunteers No
Lead Sponsor NuCana plcOther
Collaborator
Study Design
Study Phase Phase 2
Study Type Interventional
Contact Name Heather Dalton, MD
Contact Phone 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials)
Condition Ovarian Cancer
Detail for Health Professional (on clinicaltrials.gov)
More clinical trials by this PI